Eli Lilly stock gains as Foundayo data strengthen the pipeline case

Published on 10/06/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock traded at USD 1,161.69 on October 6, 2026, up 1.62 percent as Foundayo data sharpen the obesity-drug story. Q2 revenue rose 47.7 percent year over year.

Aquarellmalerei der Indianapolis-Skyline am Fluss im goldenen Abendlicht — Aquarellgemälde der Skyline von Indianapolis symbolisiert Eli Lilly and Company, ISIN US5324571083, als dortiger Pharmakonzern, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) was trading at USD 1,161.69 on the NYSE on October 6, 2026 at 11:45 a.m. ET, up 1.62 percent from the previous close. The latest company catalyst is Foundayo, whose 17.2 mg dose was associated with a predicted 57 percent reduction in 10-year type 2 diabetes risk versus placebo in analyses released on October 1, 2026.

Foundayo adds clinical momentum

According to Eli Lilly on October 1, 2026, the 17.2 mg dose also reduced predicted cardiovascular disease risk by 18 percent at 72 weeks. The Phase 3 ATTAIN-1 analysis covered 3,127 participants, giving investors a quantified view of how Lilly is extending the oral GLP-1 narrative beyond weight loss.

The release also showed a dose gradient: predicted diabetes-risk reductions were 45.0 percent at 5.5 mg, 50.0 percent at 9 mg and 57.0 percent at 17.2 mg versus placebo. The figures are modeled risk estimates, so they describe a clinical signal rather than realized disease events.

Revenue growth supports the valuation

Lilly's second-quarter 2026 revenue reached USD 22.974 billion, up 47.7 percent from the same period a year earlier, while diluted EPS was USD 7.94. The quarter's operating cash flow was USD 10.690 billion, making the commercial performance more than a single product-data story.

According to MarketBeat on September 28, 2026, JPMorgan raised its price target from USD 1,400 to USD 1,500 and kept an Overweight rating. The same report cited a Moderate Buy consensus from 30 analysts, with 26 assigning Buy or Strong Buy ratings and an average target of USD 1,311.96, which lies 12.9 percent above the October 6 intraday price.

According to Investing.com, JPMorgan expects third-quarter sales of USD 22.2 billion and EPS of USD 9.87. The report also identifies pricing pressure and execution around the oral GLP-1 rollout as factors that could test the growth premium.

Next earnings date is October 29

Eli Lilly's reference price was USD 1,161.69 on the NYSE on October 6, 2026 at 11:45 a.m. ET. The session range was USD 1,139.98 to USD 1,177.07, while the 52-week range was USD 783.85 to USD 1,292.65 and the market capitalization was USD 1.1 trillion.